Masashi Shimazaki

1.1k total citations
18 papers, 923 citations indexed

About

Masashi Shimazaki is a scholar working on Molecular Biology, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Masashi Shimazaki has authored 18 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Masashi Shimazaki's work include Cardiac Fibrosis and Remodeling (6 papers), Signaling Pathways in Disease (5 papers) and Cell Adhesion Molecules Research (5 papers). Masashi Shimazaki is often cited by papers focused on Cardiac Fibrosis and Remodeling (6 papers), Signaling Pathways in Disease (5 papers) and Cell Adhesion Molecules Research (5 papers). Masashi Shimazaki collaborates with scholars based in Japan, United States and Germany. Masashi Shimazaki's co-authors include Akira Kudō, Isao Kii, Takashi Nishiyama, Masashi Fukayama, Takeshi Kashima, Minqi Li, Norio Amizuka, Yumiko Saga, Masataka Sata and Mitsuru Saito and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Cell Biology and PLoS ONE.

In The Last Decade

Masashi Shimazaki

17 papers receiving 916 citations

Peers

Countries citing papers authored by Masashi Shimazaki

Since Specialization

Citations

This map shows the geographic impact of Masashi Shimazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masashi Shimazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masashi Shimazaki more than expected).

Fields of papers citing papers by Masashi Shimazaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masashi Shimazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masashi Shimazaki. The network helps show where Masashi Shimazaki may publish in the future.

Co-authorship network of co-authors of Masashi Shimazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Masashi Shimazaki. A scholar is included among the top collaborators of Masashi Shimazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masashi Shimazaki. Masashi Shimazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	1323 A novel bispecific antibody targeting CD137 and CLDN4 for treating patients with solid tumors 2024 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), (unknown), (unknown), Nicholas Souders, Masayasu Yoshino, (unknown), (unknown), Takeshi Saito, Masashi Shimazaki, Kenna Shirasuna	0
2	Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure–activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors 2023 ·Bioorganic & Medicinal Chemistry ·(unknown), Itsuro Shimada, (unknown), (unknown), (unknown), (unknown), (unknown), Y. Amano, Kenichi Mori, (unknown), Ayako Nakayama, (unknown), Masashi Shimazaki, Takeyuki Nagashima, (unknown)	5
3	Abstract 2962: ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models 2023 ·Cancer Research ·(unknown), Hiroaki Tanaka, (unknown), Rumana Rashid, Kendra N. Avery, Jing Qi, Alex Nisthal, Masashi Shimazaki, Kenna Shirasuna	7
4	Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity 2022 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Tomoaki Abe, (unknown), (unknown), (unknown), (unknown), Osamu Kaneko, Y. Amano, Kenichi Mori, Yosuke Yamanaka, Takeyuki Nagashima, Masashi Shimazaki, (unknown)	12
5	1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors 2022 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), Bernard A. Liu, (unknown), John J. Gosink, (unknown), (unknown), Kelly Hensley, (unknown), Albina Nesterova, (unknown), Anthony Cao, Christine O’Day, Ryan A. Heiser, Timothy S. Lewis, Shyra J. Gardai, (unknown), Masashi Shimazaki, (unknown), Sharsti Sandall	10
6	Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer 2022 ·Cancer Research ·(unknown), (unknown), (unknown), Anthony Lee, (unknown), Amit Garg, Christine O’Day, Esther S. Trueblood, Jennifer Wright, Mark Bieda, Charles W. Caldwell, Kelly Hensley, (unknown), Bernard A. Liu, Masashi Shimazaki, Sharsti Sandall	2
7	Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models 2021 ·British Journal of Cancer ·Ayako Nakayama, Takeyuki Nagashima, (unknown), (unknown), Kenichi Mori, (unknown), Masatoshi Yuri, Masashi Shimazaki	14
8	Virtual clinical trial simulations for a novel KRAS^G12C inhibitor (ASP2453) in non‐small cell lung cancer 2021 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), Takeyuki Nagashima, Masashi Shimazaki, Tsuyoshi Minematsu, Joshua F. Apgar, John M. Burke, (unknown), (unknown), Daniel C. Kirouac	9
9	Post-marketing Surveillance (PMS) of all Patients Treated with Irinotecan in Japan: Clinical Experience and ADR Profile of 13 935 Patients 2011 ·Japanese Journal of Clinical Oncology ·(unknown), (unknown), Masashi Shimazaki, (unknown), (unknown), Fumio Yamaguchi, (unknown), Y Ariyoshi, M. Fukuoka	11
10	Delayed Re-Epithelialization in Periostin-Deficient Mice during Cutaneous Wound Healing 2011 ·PLoS ONE ·Takashi Nishiyama, Isao Kii, Takeshi Kashima, Yoshinao Kikuchi, Atsushi Ohazama, Masashi Shimazaki, Masashi Fukayama, Akira Kudō	114
11	Periostin Associates with Notch1 Precursor to Maintain Notch1 Expression under a Stress Condition in Mouse Cells 2010 ·PLoS ONE ·Hideyuki Tanabe, (unknown), Takashi Nishiyama, Masashi Shimazaki, Isao Kii, Minqi Li, Norio Amizuka, Ken‐ichi Katsube, Akira Kudō	55
12	[Periostin, acting in regeneration of periodontal ligament, contributes to cardiac healing and tumor capsule formation]. 2009 ·PubMed ·Masashi Shimazaki, Akira Kudō	3
13	Periostin is essential for cardiac healingafter acute myocardial infarction 2008 ·The Journal of Experimental Medicine ·Masashi Shimazaki, Kazuto Nakamura, Isao Kii, Takeshi Kashima, Norio Amizuka, Minqi Li, Mitsuru Saito, Keiichi Fukuda, Takashi Nishiyama, Satoshi Kitajima, Yumiko Saga, Masashi Fukayama, Masataka Sata, Akira Kudō	388
14	Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos–overexpressing bone lesions 2008 ·Human Pathology ·Takeshi Kashima, Takashi Nishiyama, Kazuhiro Shimazu, Masashi Shimazaki, Isao Kii, Agamemnon E. Grigoriadis, Masashi Fukayama, Akira Kudō	79
15	Impaired capsule formation of tumors in periostin-null mice 2008 ·Biochemical and Biophysical Research Communications ·Masashi Shimazaki, Akira Kudō	31
16	Periostin is essential for cardiac healing after acute myocardial infarction 2008 ·The Journal of Cell Biology ·Masashi Shimazaki, Kazuto Nakamura, Isao Kii, Takeshi Kashima, Norio Amizuka, Minqi Li, Mitsuru Saito, Keiichi Fukuda, Takashi Nishiyama, Satoshi Kitajima, (unknown), Masashi Fukayama, Masataka Sata, Akira Kudō	11
17	Periostin Is Expressed in Pericryptal Fibroblasts and Cancer-associated Fibroblasts in the Colon 2008 ·Journal of Histochemistry & Cytochemistry ·Yoshinao Kikuchi, Takeshi Kashima, Takashi Nishiyama, Kazuhiro Shimazu, Yasuyuki Morishita, Masashi Shimazaki, Isao Kii, Hisanaga Horie, Hideo Nagai, Akira Kudō, Masashi Fukayama	114
18	GFP transgenic mice reveal active canonical Wnt signal in neonatal brain and in adult liver and spleen 2007 ·genesis ·(unknown), Isao Kii, Takehiko Sunabori, (unknown), (unknown), Masashi Shimazaki, Hideyuki Tanabe, Masayuki Oginuma, Masashi Fukayama, Yumi Matsuzaki, Yumiko Saga, Akira Kudō	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact